• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进行性骨化性纤维发育不良患者外周血单个核细胞免疫表型分析:单核细胞 DNAM1 上调的证据。

Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation.

机构信息

IRCCS Istituto Giannina Gaslini, Genova, Italy.

Department of Biomolecular Sciences, University of Urbino, Pesaro-Urbino, Italy.

出版信息

Cytometry B Clin Cytom. 2018 Jul;94(4):613-622. doi: 10.1002/cyto.b.21594. Epub 2017 Nov 15.

DOI:10.1002/cyto.b.21594
PMID:28985649
Abstract

BACKGROUND

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by sporadic heterozygous mutations in ACVR1 gene which progressively leads to severe heterotopic ossification. FOP is characterized by episodic flare-ups triggered by different factors such as viral infections, tissue injuries, vaccinations, or occurring without a recognizable cause. The sporadic course of the disease, the documented presence of an important inflammatory reaction in early lesions and the partial response to corticosteroids support the idea that the immune system, and in particular the innate component, may play a role in FOP pathogenesis. However, an extensive expression profile of the peripheral blood mononuclear cells (PBMC) of FOP patients has never been done.

METHODS

In this study, we carried out a wide PBMC immunophenotyping on a cohort of FOP patients and matching controls by multiparametric analysis of the expression of a panel of 37 markers associated with migration, adhesion, inhibition, activation, and cell death of circulating immune cells.

RESULTS

We observed a statistically significant increase of the expression of DNAM1 receptor in patients' monocytes as compared to controls, and little but significant differences in the expression profile of CXCR1 (CD181), CD62L, CXCR4 (CD184), and HLA-DR molecules.

CONCLUSIONS

DNAM1 had been previously shown to play a pivotal role in monocyte migration through the endothelial barrier and the increased expression detected in patients' monocytes might suggest a role of this surface receptor during the early phases of FOP flare-ups in which the activation of the immune response is believed to represent a crucial event. © 2017 International Clinical Cytometry Society.

摘要

背景

成骨不全症(FOP)是一种罕见的遗传性疾病,由 ACVR1 基因突变引起,这些突变导致严重的异位骨化。FOP 的特征是由不同因素触发的阵发性发作,如病毒感染、组织损伤、疫苗接种,或无明显原因发生。疾病的散发性病程、早期病变中存在明显的炎症反应以及对皮质类固醇的部分反应支持免疫系统,特别是固有成分,可能在 FOP 发病机制中发挥作用。然而,FOP 患者外周血单核细胞(PBMC)的广泛表达谱从未被研究过。

方法

在这项研究中,我们通过对一组 FOP 患者和匹配对照者的 PBMC 进行 37 种标志物的表达的多参数分析,对其进行了广泛的 PBMC 免疫表型分析,这些标志物与循环免疫细胞的迁移、黏附、抑制、激活和细胞死亡有关。

结果

与对照组相比,我们观察到患者单核细胞中 DNAM1 受体的表达显著增加,而 CXCR1(CD181)、CD62L、CXCR4(CD184)和 HLA-DR 分子的表达谱略有但有统计学意义的差异。

结论

DNAM1 先前被证明在单核细胞通过内皮屏障的迁移中起着关键作用,在患者单核细胞中检测到的表达增加可能表明在 FOP 发作的早期阶段,这种表面受体可能发挥作用,而在这一阶段,免疫反应的激活被认为是一个关键事件。

相似文献

1
Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation.进行性骨化性纤维发育不良患者外周血单个核细胞免疫表型分析:单核细胞 DNAM1 上调的证据。
Cytometry B Clin Cytom. 2018 Jul;94(4):613-622. doi: 10.1002/cyto.b.21594. Epub 2017 Nov 15.
2
Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?纤维发育不良性骨化性进展症患者血浆 RANTES 升高——新的治疗靶点?
Med Hypotheses. 2019 Oct;131:109313. doi: 10.1016/j.mehy.2019.109313. Epub 2019 Jul 20.
3
Inhibition of TGFβ signaling decreases osteogenic differentiation of fibrodysplasia ossificans progressiva fibroblasts in a novel in vitro model of the disease.在一种新型疾病体外模型中,抑制转化生长因子β信号传导可降低进行性骨化性纤维发育不良成纤维细胞的成骨分化。
Bone. 2016 Mar;84:169-180. doi: 10.1016/j.bone.2016.01.004. Epub 2016 Jan 6.
4
Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)患者的纵向报告移动性评估。
Bone. 2018 Apr;109:158-161. doi: 10.1016/j.bone.2017.06.005. Epub 2017 Jun 6.
5
Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients.激活素-A 可诱导健康对照者和进行性骨化性纤维发育不良患者的单核细胞生成数量较少但体积较大的破骨细胞。
Front Endocrinol (Lausanne). 2020 Jul 14;11:501. doi: 10.3389/fendo.2020.00501. eCollection 2020.
6
The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.进行性骨化性纤维发育不良(FOP)发作的自然史:一项全面的全球评估。
J Bone Miner Res. 2016 Mar;31(3):650-6. doi: 10.1002/jbmr.2728. Epub 2015 Nov 14.
7
Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.长期使用白细胞介素-1 抑制剂可减少进行性骨化性纤维发育不良患者的发作活动。
Rheumatology (Oxford). 2024 Sep 1;63(9):2597-2604. doi: 10.1093/rheumatology/keae255.
8
Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.纤维性骨发育不良进展性的影像学评估:定性、定量和可疑。
Bone. 2018 Apr;109:147-152. doi: 10.1016/j.bone.2017.08.011. Epub 2017 Aug 16.
9
Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)中的急性单侧髋关节疼痛。
Bone. 2018 Apr;109:115-119. doi: 10.1016/j.bone.2017.08.009. Epub 2017 Aug 16.
10
Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).肥大细胞抑制作为进行性骨化性纤维发育不良(FOP)的治疗方法。
Bone. 2018 Apr;109:259-266. doi: 10.1016/j.bone.2017.08.023. Epub 2017 Aug 26.

引用本文的文献

1
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.进行性骨化性纤维发育不良的发病机制及药物治疗进展
J Zhejiang Univ Sci B. 2025 Apr 23;26(4):317-332. doi: 10.1631/jzus.B2300779.
2
Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification.纤维性骨发育不良与创伤性异位骨化的交集。
Biomolecules. 2024 Mar 14;14(3):349. doi: 10.3390/biom14030349.
3
Human iPSCs as Model Systems for BMP-Related Rare Diseases.人诱导多能干细胞作为 BMP 相关罕见病的模型系统。
Cells. 2023 Sep 2;12(17):2200. doi: 10.3390/cells12172200.
4
Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.使用 FOP 患者来源的 iPSCs 对具有 ACVR1A 突变的单核细胞的促炎特征进行概括。
Orphanet J Rare Dis. 2022 Sep 21;17(1):364. doi: 10.1186/s13023-022-02506-3.
5
Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop.骨化性纤维发育不良进展性:我们已经取得了哪些成就,现在又在哪里?对 2015 年洛伦茨研讨会的跟进。
Front Endocrinol (Lausanne). 2021 Nov 10;12:732728. doi: 10.3389/fendo.2021.732728. eCollection 2021.
6
Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment.罕见且难治的进行性骨化性纤维发育不良表现出不同的外周血单核细胞表型,可能受到抗坏血酸和普萘洛尔治疗的调节。
Intractable Rare Dis Res. 2021 Aug;10(3):179-189. doi: 10.5582/irdr.2021.01012.
7
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良中药物重新定位的挑战与机遇
Biomedicines. 2021 Feb 19;9(2):213. doi: 10.3390/biomedicines9020213.
8
Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.纤维性骨发育不良性骨化性纤维发育不良和其他形式的异位骨化中的炎症。
Curr Osteoporos Rep. 2019 Dec;17(6):387-394. doi: 10.1007/s11914-019-00541-x.
9
NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.ACVR1 介导的炎症反应中 NF-κB/MAPK 的激活作用。
JCI Insight. 2018 Nov 15;3(22):122958. doi: 10.1172/jci.insight.122958.
10
The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.罕见遗传性疾病治疗的新曙光:成骨不全性骨纤维发育异常的“可成药”未来。
Int J Mol Sci. 2018 Mar 26;19(4):989. doi: 10.3390/ijms19040989.